Somatic/JJ
Mutaome/NN
Profile/JJ
in/IN
Human/JJ
Cancer/NN
Tissues/NNS
./.
====================
Somatic/JJ
mutation/NN
is/VBZ
a/DT
major/JJ
cause/VBP
of/IN
cancer/NN
progression/NN
and/CC
varied/VBD
responses/NNS
of/IN
tumors/NNS
against/IN
anticancer/JJ
agents/NNS
./.
====================
Thus/RB
,/,
we/PRP
must/MD
obtain/VB
and/CC
characterize/VBP
genome-wide/NN
mutational/JJ
profiles/NNS
in/IN
individual/JJ
cancer/NN
subtypes/NNS
./.
====================
The/DT
Cancer/NN
Genome/NN
Atlas/NNS
database/NN
includes/VBZ
large/JJ
amounts/NNS
of/IN
sequencing/NN
and/CC
omics/NNS
data/NNS
generated/VBD
from/IN
diverse/JJ
human/JJ
cancer/NN
tissues/NNS
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
we/PRP
integrated/VBD
and/CC
analyzed/VBD
the/DT
exome/JJ
sequencing/NN
data/NNS
from/IN
~3,000/CD
tissue/NN
samples/NNS
and/CC
summarized/VBD
the/DT
major/JJ
mutant/JJ
genes/NNS
in/IN
each/DT
of/IN
the/DT
diverse/JJ
cancer/NN
subtypes/NNS
and/CC
stages/NNS
./.
====================
Mutations/NNS
were/VBD
observed/VBN
in/IN
most/JJS
human/JJ
genes/NNS
(/(
~23,000/CD
genes/NNS
)/)
with/IN
low/JJ
frequency/NN
from/IN
an/DT
analysis/NN
of/IN
11/CD
major/JJ
cancer/NN
subtypes/NNS
./.
====================
The/DT
majority/NN
of/IN
tissue/NN
samples/NNS
harbored/VBD
20-80/CD
different/JJ
mutant/JJ
genes/NNS
,/,
on/IN
average/NN
./.
====================
Lung/NN
cancer/NN
samples/NNS
showed/VBD
a/DT
greater/JJR
number/NN
of/IN
mutations/NNS
in/IN
diverse/JJ
genes/NNS
than/IN
other/JJ
cancer/NN
subtypes/NNS
./.
====================
Only/RB
a/DT
few/JJ
genes/NNS
were/VBD
mutated/VBN
with/IN
over/IN
5/CD
%/NN
frequency/NN
in/IN
tissue/NN
samples/NNS
./.
====================
Interestingly/RB
,/,
mutation/NN
frequency/NN
was/VBD
generally/RB
similar/JJ
between/IN
non-metastatic/JJ
and/CC
metastastic/JJ
samples/NNS
in/IN
most/JJS
cancer/NN
subtypes/NNS
./.
====================
Among/IN
the/DT
12/CD
major/JJ
mutations/NNS
,/,
the/DT
TP53/NN
,/,
USH2A/NN
,/,
TTN/NN
,/,
and/CC
MUC16/NN
genes/NNS
were/VBD
found/VBN
to/TO
be/VB
frequent/JJ
in/IN
most/JJS
cancer/NN
types/NNS
,/,
while/IN
BRAF/NN
,/,
FRG1B/NN
,/,
PBRM1/NN
,/,
and/CC
VHL/NN
showed/VBD
lineage-specific/JJ
mutation/NN
patterns/NNS
./.
====================
The/DT
present/JJ
study/NN
provides/VBZ
a/DT
useful/JJ
resource/NN
to/TO
understand/VB
the/DT
broad/JJ
spectrum/NN
of/IN
mutation/NN
frequencies/NNS
in/IN
various/JJ
cancer/NN
types/NNS
./.
====================
Recent/JJ
progress/NN
in/IN
high-throughput/JJ
sequencing/NN
technology/NN
has/VBZ
contributed/VBN
to/TO
the/DT
generation/NN
of/IN
genome-wide/NN
somatic/JJ
mutation/NN
profiles/NNS
in/IN
diverse/JJ
cancer/NN
samples/NNS
./.
====================
The/DT
Cancer/NN
Genome/NN
Atlas/NNS
(/(
TCGA/NN
)/)
is/VBZ
one/CD
of/IN
largest/JJS
collaborative/JJ
efforts/NNS
to/TO
generate/VB
multi-level/JJ
omics/NNS
data/NNS
on/IN
human/JJ
cancer/NN
tissue/NN
samples/NNS
./.
====================
Particularly/RB
,/,
information/NN
on/IN
genome-wide/NN
somatic/JJ
mutations/NNS
has/VBZ
been/VBN
collectively/RB
profiled/VBD
from/IN
exome/DT
sequencing/NN
data/NNS
from/IN
thousands/DT
of/IN
patients/NNS
'/``
tumor/NN
samples/NNS
./.
====================
Somatic/JJ
mutation/NN
is/VBZ
a/DT
main/JJ
driving/VBG
force/VBP
for/IN
cancer/NN
development/NN
and/CC
progression/NN
./.
====================
Thus/RB
,/,
many/JJ
researchers/NNS
have/VBP
tried/VBN
to/TO
complete/JJ
the/DT
catalog/NN
of/IN
somatic/JJ
mutations/NNS
in/IN
cancer/NN
cell/NN
lines/NNS
[/(
1/CD
,/,
2/CD
]/)
./.
====================
Somatic/JJ
mutation/NN
is/VBZ
also/RB
known/VBN
to/TO
be/VB
involved/VBN
in/IN
key/JJ
mechanisms/NNS
for/IN
cellular/JJ
sensitivity/NN
or/CC
resistance/NN
against/IN
chemotherapy/NN
[/(
3-5/CD
]/)
./.
====================
In/IN
our/PRP$
previous/JJ
study/NN
using/VBG
cancer/NN
cell/NN
line/NN
data/NNS
,/,
we/PRP
reported/VBD
that/IN
somatic/JJ
mutation/NN
was/VBD
a/DT
more/RBR
significant/JJ
classifier/NN
than/IN
cancer/NN
lineage/NN
in/IN
predicting/VBG
the/DT
anticancer/JJ
drug/NN
response/NN
[/(
6/CD
]/)
./.
====================
Thus/RB
,/,
we/PRP
identified/VBD
many/JJ
unknown/JJ
association/NN
patterns/NNS
between/IN
cancer/NN
drug/NN
response/NN
and/CC
mutational/JJ
genotypes/NNS
in/IN
cancer/NN
cell/NN
lines-e.g./NN
,/,
MYC-amp/NN
mutation-specific/JJ
sensitivity/NN
of/IN
insulin-like/JJ
growth/NN
factor/NN
1/CD
receptor/NN
inhibitors/NNS
./.
====================
In/IN
addition/NN
,/,
mutation/NN
information/NN
provided/VBD
important/JJ
clues/NNS
for/IN
us/PRP
to/TO
better/RBR
interpret/VB
the/DT
biological/JJ
relevance/NN
of/IN
molecular/JJ
signatures/NNS
identified/VBN
from/IN
the/DT
transcriptome/JJ
and/CC
proteome/VBP
data/NNS
of/IN
diverse/JJ
cancer/NN
cell/NN
lines/NNS
./.
====================
The/DT
next/JJ
step/NN
should/MD
be/VB
to/TO
find/VB
out/IN
the/DT
clinical/JJ
application/NN
of/IN
mutation-specific/JJ
drug/NN
responses/NNS
or/CC
molecular/JJ
signatures/NNS
obtained/VBN
from/IN
cell/NN
line-based/JJ
analysis/NN
./.
====================
Thus/RB
,/,
it/PRP
is/VBZ
important/JJ
to/TO
systematically/RB
analyze/VB
the/DT
mutational/JJ
genotype/NN
(/(
mutaome/NN
)/)
of/IN
various/JJ
human/JJ
tissue/NN
samples/NNS
and/CC
identify/VBP
mutations/NNS
significantly/RB
associated/VBN
with/IN
specific/JJ
types/NNS
of/IN
tumors/NNS
./.
====================
'Mutaome/DT
'/``
means/NNS
the/DT
cancer/NN
mutational/JJ
landscape/NN
,/,
including/VBG
mutations/NNS
in/IN
oncogenes/NNS
and/CC
tumor/NN
suppressors/NNS
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
we/PRP
organized/VBD
all/DT
sequence-based/VBN
mutation/NN
information/NN
into/IN
gene-based/VBN
frequency/NN
data/NNS
./.
====================
Then/RB
,/,
we/PRP
comparatively/RB
determined/VBN
the/DT
major/JJ
genes/NNS
of/IN
somatic/JJ
mutations/NNS
in/IN
diverse/JJ
cancer/NN
subtypes/NNS
and/CC
cancer/NN
stages/NNS
(/(
i.e./FW
,/,
non-metastatic/JJ
and/CC
metastatic/JJ
samples/NNS
)/)
./.
====================
This/DT
work/NN
will/MD
provide/VB
practical/JJ
information/NN
for/IN
directing/VBG
in/IN
vitro/FW
cell/NN
line-based/JJ
mutation-specific/JJ
phenotypes/NNS
to/TO
clinical/JJ
applications/NNS
in/IN
cancer/NN
drug/NN
discovery/NN
and/CC
mechanism/NN
studies/NNS
./.
====================
Data/NNS
acquisition/NN
====================
Somatic/JJ
mutation/NN
data/NNS
for/IN
tumor/NN
tissue/NN
samples/NNS
from/IN
2938/CD
patients/NNS
,/,
harboring/VBG
11/CD
cancer/NN
types/NNS
,/,
were/VBD
obtained/VBN
from/IN
the/DT
data/NNS
portal/JJ
of/IN
TCGA/NN
,/,
which/WDT
were/VBD
freely/RB
available/JJ
./.
====================
These/DT
data/NNS
(/(
level/NN
2/CD
)/)
for/IN
10/CD
cancer/NN
types/NNS
,/,
except/IN
ovarian/JJ
serous/JJ
cy_stadenocarcinoma/NN
(/(
OV/NN
)/)
,/,
provide/VBP
genome-wide/NN
somatic/JJ
mutations/NNS
on/IN
each/DT
sample/NN
experimented/VBN
with/IN
the/DT
Illumina/NN
Genome/NN
Analyzer/NN
DNA/NN
Sequencing/NN
platform/NN
(/(
Illumina/NN
,/,
San/NNP
Diego/JJ
,/,
CA/NNP
,/,
USA/NNP
)/)
./.
====================
The/DT
somatic/JJ
mutation/NN
data/NNS
for/IN
OV/NN
were/VBD
organized/VBN
,/,
combined/JJ
with/IN
data/NNS
produced/VBD
from/IN
Illumina/NN
and/CC
the/DT
ABI/NN
SOLiD/NN
DNA/NN
System/NN
Sequencing/NN
platforms/NNS
(/(
Applied/VBN
Biosystems/NNS
,/,
Foster/NN
City/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
./.
====================
The/DT
details/NNS
,/,
including/VBG
the/DT
full/JJ
name/NN
of/IN
each/DT
cancer/NN
type/NN
and/CC
updated/VBD
dates/NNS
of/IN
mutation/NN
data/NNS
,/,
are/VBP
provided/VBN
in/IN
Table/JJ
1/CD
./.
====================
Together/RB
with/IN
somatic/JJ
mutation/NN
data/NNS
,/,
clinical/JJ
data/NNS
for/IN
each/DT
patient/NN
were/VBD
downloaded/VBN
from/IN
the/DT
data/NNS
portal/JJ
of/IN
TCGA/NN
./.
====================
These/DT
data/NNS
were/VBD
applied/VBN
to/TO
categorize/VB
samples/NNS
into/IN
metastasis/NN
and/CC
non-metastasis/NN
./.
====================
The/DT
annotation/NN
of/IN
'pathologic_M/JJ
'/``
was/VBD
available/JJ
to/TO
indicate/VB
the/DT
stage/NN
of/IN
metastasis/NN
in/IN
the/DT
patient/NN
's/POS
tumor/NN
samples/NNS
./.
====================
The/DT
stage/NN
of/IN
M0/NN
'/``
means/NNS
that/DT
there/EX
was/VBD
no/DT
evidence/NN
of/IN
distant/JJ
metastasis/NN
,/,
and/CC
'M1/NN
'/``
means/NNS
that/DT
a/DT
pathological/JJ
distant/JJ
metastasis/NN
was/VBD
found/VBN
./.
====================
In/IN
this/DT
study/NN
,/,
the/DT
samples/NNS
from/IN
patients/NNS
annotated/VBD
as/IN
'M0/CD
'/``
were/VBD
classified/VBN
as/IN
non-metastatic/JJ
,/,
and/CC
those/DT
with/IN
'M1/NN
'/``
were/VBD
classified/VBN
as/IN
metastatic/JJ
./.
====================
Analysis/NN
of/IN
somatic/JJ
mutations/NNS
====================
The/DT
number/NN
of/IN
detected/VBN
mutations/NNS
in/IN
each/DT
cancer/NN
type/NN
ranged/VBD
from/IN
tens/NNS
to/TO
hundreds/VBZ
of/IN
thousands/NNS
./.
====================
We/PRP
organized/VBD
the/DT
detected/VBN
point/NN
mutations/NNS
into/IN
23,050/CD
human/JJ
genes/NNS
./.
====================
The/DT
number/NN
of/IN
mutant/JJ
genes/NNS
per/IN
sample/NN
was/VBD
counted/VBN
for/IN
~3,000/CD
samples/NNS
./.
====================
In/IN
addition/NN
,/,
the/DT
mutation/NN
frequency/NN
and/CC
its/PRP$
percentage/NN
were/VBD
calculated/VBN
for/IN
all/DT
samples/NNS
and/CC
each/DT
cancer/NN
type/NN
./.
====================
The/DT
major/JJ
mutant/JJ
genes/NNS
that/WDT
ranked/VBD
within/IN
the/DT
top/NN
3/CD
in/IN
each/DT
cancer/NN
type/NN
were/VBD
selected/VBN
based/VBN
on/IN
the/DT
observed/VBN
frequency/NN
in/IN
the/DT
overall/JJ
,/,
non-metastatic/JJ
,/,
and/CC
metastatic/JJ
samples/NNS
./.
====================
The/DT
patterns/NNS
of/IN
frequency/NN
for/IN
the/DT
selected/VBN
major/JJ
genes/NNS
were/VBD
analyzed/VBN
through/IN
hierarchical/JJ
clustering/NN
method/NN
./.
====================
The/DT
clustering/NN
and/CC
its/PRP$
visualization/NN
on/IN
a/DT
heatmap/JJ
were/VBD
performed/VBN
using/VBG
the/DT
software/JJ
QCanvas/NNS
[/(
7/CD
]/)
./.
====================
QCanvas/NNS
can/MD
be/VB
down-loaded/VBN
freely/RB
from/IN
the/DT
website/JJ
http/NN
:/:
//compbio.sookmyung.ac.kr/~qcanvas/NNS
./.
====================
Mutation/NN
frequency/NN
in/IN
patients/NNS
'/``
tumor/NN
samples/NNS
====================
From/IN
the/DT
TCGA/NN
database/NN
,/,
thousands/VBZ
of/IN
patients/NNS
'/``
tumor/NN
samples/NNS
were/VBD
analyzed/VBN
to/TO
detect/VB
variants/NNS
in/IN
the/DT
whole/JJ
genome/NN
./.
====================
To/TO
quantify/VB
the/DT
genome-wide/NN
mutation/NN
profile/NN
in/IN
diverse/JJ
tumors/NNS
,/,
we/PRP
organized/VBD
the/DT
whole/JJ
mutant/JJ
genes/NNS
into/IN
several/JJ
cancer/NN
types/NNS
and/CC
stages/NNS
,/,
using/VBG
the/DT
annotation/NN
information/NN
obtained/VBN
from/IN
TCGA/NN
./.
====================
Overall/RB
,/,
a/DT
total/JJ
of/IN
871,684/CD
mutations/NNS
were/VBD
virtually/RB
found/VBN
in/IN
23,050/CD
human/JJ
genes/NNS
from/IN
2,938/CD
patient/NN
tumor/NN
samples/NNS
(/(
Table/JJ
1/CD
)/)
./.
====================
Samples/NNS
covered/VBD
11/CD
diverse/JJ
cancer/NN
types/NNS
(/(
Table/JJ
1/CD
)/)
./.
====================
These/DT
data/NNS
were/VBD
continuously/RB
updated/VBD
and/CC
produced/VBD
by/IN
analyzing/VBG
additional/JJ
samples/NNS
./.
====================
Together/RB
with/IN
the/DT
extended/JJ
production/NN
of/IN
multi-level/JJ
omics/NNS
data/NNS
using/VBG
the/DT
same/JJ
patients/NNS
'/``
tissue/NN
samples/NNS
,/,
TCGA/NN
provides/VBZ
a/DT
useful/JJ
resource/NN
for/IN
understanding/VBG
the/DT
role/NN
of/IN
mutations/NNS
in/IN
cancer/NN
progression/NN
./.
====================
The/DT
distribution/NN
of/IN
mutant/JJ
genes/NNS
on/IN
each/DT
sample/NN
showed/VBD
that/IN
a/DT
variety/NN
of/IN
genes/NNS
are/VBP
mutated/VBN
in/IN
individual/JJ
tumor/NN
samples/NNS
./.
====================
Most/JJS
samples/NNS
contained/VBD
on/IN
average/NN
20-80/CD
mutations/NNS
(/(
Fig/NN
./.
====================
1A/NN
)/)
./.
====================
This/DT
means/NNS
that/DT
each/DT
single/JJ
tumor/NN
sample/NN
has/VBZ
mutations/NNS
in/IN
multiple/JJ
genes/NNS
./.
====================
Various/JJ
mutations/NNS
in/IN
a/DT
cancer/NN
sample/NN
were/VBD
already/RB
well-characterized/JJ
and/CC
constructed/VBD
as/IN
open/JJ
source/NN
data/NNS
[/(
8/CD
]/)
,/,
and/CC
the/DT
significance/NN
of/IN
multiple/JJ
mutations/NNS
in/IN
a/DT
single/JJ
tumor/NN
has/VBZ
been/VBN
constantly/RB
suggested/VBD
[/(
9/CD
,/,
10/CD
]/)
./.
====================
It/PRP
is/VBZ
appropriate/JJ
that/DT
a/DT
tumor/NN
may/MD
also/RB
consist/VBP
of/IN
a/DT
heterogeneous/JJ
collection/NN
of/IN
cells/NNS
with/IN
different/JJ
types/NNS
of/IN
mutations/NNS
./.
====================
Furthermore/RB
,/,
in/IN
the/DT
aspect/NN
of/IN
lineage/NN
dependency/NN
,/,
the/DT
amount/NN
of/IN
mutations/NNS
in/IN
individual/JJ
samples/NNS
varied/VBN
,/,
depending/VBG
on/IN
cancer/NN
type/NN
(/(
Fig/NN
./.
====================
1C/NN
)/)
./.
====================
Lung/NN
adenocarcinoma/NN
samples/NNS
have/VBP
a/DT
wide/JJ
range/NN
of/IN
mutation/NN
frequencies/NNS
in/IN
individual/JJ
samples/NNS
and/CC
harbor/VBP
more/RBR
mutations/NNS
than/IN
other/JJ
lineages/NNS
./.
====================
The/DT
broad/JJ
range/NN
of/IN
mutation/NN
frequencies/NNS
in/IN
lung/NN
cancer/NN
was/VBD
also/RB
referred/VBN
to/TO
in/IN
Lawrence/NN
et/FW
al/JJ
./.
====================
[/(
11/CD
]/)
./.
====================
In/IN
contrast/NN
,/,
thyroid/NN
carcinoma/NN
has/VBZ
relatively/RB
few/JJ
mutations/NNS
in/IN
individual/JJ
samples/NNS
./.
====================
Further/RB
studies/NNS
are/VBP
required/VBN
to/TO
understand/VB
the/DT
association/NN
with/IN
the/DT
amounts/NNS
of/IN
mutations/NNS
and/CC
major/JJ
biological/JJ
factors/NNS
in/IN
each/DT
cancer/NN
type/NN
./.
====================
This/DT
can/MD
be/VB
analyzed/VBN
by/IN
comparing/VBG
with/IN
the/DT
patient/NN
's/POS
clinical/JJ
information/NN
,/,
including/VBG
smoking/NN
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
the/DT
mutation/NN
of/IN
each/DT
gene/NN
was/VBD
observed/VBN
at/IN
a/DT
very/RB
low/JJ
frequency/NN
in/IN
all/DT
samples/NNS
(/(
Fig/NN
./.
====================
1B/NN
)/)
./.
====================
Most/JJS
genes/NNS
contained/VBD
mutations/NNS
in/IN
less/RBR
than/IN
1/CD
%/NN
of/IN
samples/NNS
,/,
and/CC
only/RB
a/DT
few/JJ
genes/NNS
contained/VBD
mutations/NNS
in/IN
over/IN
5/CD
%/NN
of/IN
all/DT
samples/NNS
./.
====================
Generally/RB
,/,
the/DT
mutation/NN
of/IN
a/DT
gene/NN
showed/VBD
low/JJ
frequency/NN
in/IN
all/DT
cancer/NN
types/NNS
,/,
except/IN
in/IN
uterine/JJ
corpus/NN
endometrioid/JJ
carcinoma/NN
(/(
UCEC/NN
)/)
(/(
Fig/NN
./.
====================
1D/CD
)/)
./.
====================
Mutant/JJ
genes/NNS
were/VBD
found/VBN
in/IN
2.4/CD
%/NN
of/IN
UCEC/NN
samples/NNS
(/(
>/JJR
2-fold/JJ
greater/JJR
than/IN
other/JJ
lineages/NNS
)/)
,/,
and/CC
sometimes/RB
,/,
a/DT
gene/NN
showed/VBD
a/DT
mutation/NN
in/IN
>/JJR
8/CD
%/NN
of/IN
UCEC/NN
tumors/NNS
./.
====================
In/IN
conclusion/NN
,/,
there/EX
are/VBP
only/RB
a/DT
few/JJ
genes/NNS
in/IN
which/WDT
mutations/NNS
are/VBP
frequently/RB
(/(
i.e./FW
,/,
>/JJR
1-2/CD
%/NN
)/)
found/VBD
in/IN
tumor/NN
./.
====================
Genes/NNS
with/IN
relatively/RB
frequent/JJ
mutations/NNS
in/IN
tumors/NNS
may/MD
have/VB
a/DT
significant/JJ
role/NN
in/IN
cancer/NN
progression/NN
./.
====================
Comparative/JJ
analysis/NN
of/IN
mutations/NNS
between/IN
non-metastatic/JJ
and/CC
metastatic/JJ
samples/NNS
====================
TCGA/NN
provides/VBZ
annotations/NNS
for/IN
the/DT
stage/NN
of/IN
metastasis/NN
in/IN
each/DT
patient/NN
sample/NN
from/IN
the/DT
clinical/JJ
data/NNS
./.
====================
According/VBG
to/TO
these/DT
data/NNS
,/,
thousands/VBZ
of/IN
samples/NNS
for/IN
8/CD
cancer/NN
types/NNS
,/,
except/IN
for/IN
OV/NN
,/,
glioblastoma/NN
multiforme/JJ
(/(
GBM/NN
)/)
,/,
and/CC
UCEC/NN
,/,
were/VBD
classified/VBN
into/IN
89/CD
metastatic/JJ
and/CC
1341/CD
non-metastatic/JJ
samples/NNS
in/IN
order/NN
to/TO
compare/VB
the/DT
mutation/NN
frequency/NN
between/IN
them/PRP
./.
====================
The/DT
annotation/NN
for/IN
metastasis/NN
was/VBD
not/RB
provided/VBN
for/IN
the/DT
excluded/VBN
cancer/NN
types-OV/NN
,/,
GBM/NN
,/,
and/CC
UCEC/NN
./.
====================
Interestingly/RB
,/,
metastatic/JJ
samples/NNS
had/VBD
similar/JJ
mutation/NN
frequencies/NNS
as/IN
non-metastatic/JJ
samples/NNS
for/IN
most/JJS
cancer/NN
types/NNS
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
Kidney/NN
renal/JJ
clear/JJ
cell/NN
carcinoma/NN
(/(
KIRC/NN
)/)
had/VBD
significant/JJ
(/(
p/NN
</JJR
0.01/CD
)/)
difference/NN
in/IN
frequency/NN
between/IN
metastatic/JJ
and/CC
non-metastatic/JJ
samples/NNS
./.
====================
This/DT
result/NN
implied/VBD
that/DT
there/EX
is/VBZ
no/DT
differential/JJ
occurrence/NN
of/IN
mutations/NNS
between/IN
metastatic/JJ
and/CC
non-metastatic/JJ
samples/NNS
,/,
except/IN
in/IN
minor/JJ
case/NN
./.
====================
Identification/NN
of/IN
major/JJ
mutant/NN
genes/NNS
====================
In/IN
this/DT
study/NN
,/,
the/DT
mutation/NN
frequency/NN
was/VBD
analyzed/VBN
separately/RB
in/IN
overall/JJ
,/,
non-metastatic/JJ
,/,
and/CC
metastatic/JJ
samples/NNS
./.
====================
We/PRP
focused/VBD
on/IN
mutant/JJ
genes/NNS
exhibiting/VBG
high/JJ
frequency/NN
in/IN
each/DT
sample/NN
group/NN
./.
====================
A/DT
total/JJ
of/IN
12/CD
,/,
10/CD
,/,
and/CC
15/CD
genes/NNS
were/VBD
ranked/VBN
within/IN
the/DT
top/NN
3/CD
mutations/NNS
in/IN
at/IN
least/JJS
one/CD
of/IN
cancer/NN
type/NN
in/IN
the/DT
overall/JJ
,/,
non-metastatic/JJ
,/,
and/CC
metastatic/JJ
samples/NNS
,/,
respectively/RB
(/(
Table/JJ
2/CD
)/)
./.
====================
Especially/RB
,/,
TP53/NN
and/CC
TTN/NN
showed/VBD
dominant/JJ
frequencies/NNS
for/IN
over/IN
1,000/CD
of/IN
all/DT
samples/NNS
./.
====================
In/IN
addition/NN
,/,
the/DT
pattern/NN
of/IN
mutation/NN
frequency/NN
for/IN
the/DT
selected/VBN
major/JJ
mutant/JJ
genes/NNS
was/VBD
analyzed/VBN
in/IN
diverse/JJ
cancer/NN
categories/NNS
(/(
Fig/NN
./.
====================
3/CD
)/)
./.
====================
Regardless/RB
of/IN
sample/JJ
group/NN
,/,
MUC16/NN
,/,
TTN/NN
,/,
and/CC
TP53/NN
were/VBD
found/VBN
to/TO
be/VB
frequent/JJ
in/IN
most/JJS
cancer/NN
types/NNS
./.
====================
TP53/NN
is/VBZ
a/DT
well-known/JJ
mutant/JJ
gene/NN
,/,
playing/VBG
an/DT
important/JJ
role/NN
in/IN
cancer/NN
progression/NN
[/(
12/CD
,/,
13/CD
]/)
./.
====================
It/PRP
was/VBD
reported/VBN
that/IN
TP53/NN
mutation/NN
is/VBZ
frequently/RB
represented/VBN
in/IN
major/JJ
cancer/NN
lineages/NNS
[/(
6/CD
]/)
./.
====================
Mutation/NN
TTN/NN
and/CC
MUC16/NN
has/VBZ
not/RB
been/VBN
reported/VBN
to/TO
be/VB
critical/JJ
in/IN
cancers/NNS
./.
====================
This/DT
analysis/NN
shows/VBZ
that/IN
they/PRP
may/MD
have/VB
potential/JJ
,/,
specific/JJ
roles/NNS
in/IN
cancer/NN
development/NN
or/CC
progression/NN
./.
====================
Among/IN
12/CD
major/JJ
mutant/JJ
genes/NNS
selected/VBN
from/IN
the/DT
overall/JJ
samples/NNS
,/,
BRAF/NN
,/,
FRG1B/NN
,/,
PBRM1/NN
,/,
and/CC
VHL/NN
had/VBD
cancer/NN
subtype-specific/JJ
mutation/NN
patterns/NNS
(/(
Fig/NN
./.
====================
3A/NN
)/)
./.
====================
Especially/RB
,/,
PBRM1/NN
and/CC
VHL/NN
showed/VBD
strong/JJ
specificity/NN
in/IN
KIRC/NN
tumors/NNS
./.
====================
As/IN
previously/RB
reported/VBD
[/(
14/CD
]/)
,/,
the/DT
alterations/NNS
of/IN
VHL/NN
(/(
a/DT
tumor/NN
suppressor/NN
gene/NN
)/)
are/VBP
clearly/RB
dominant/JJ
in/IN
renal/JJ
cell/NN
carcinoma/NN
./.
====================
Together/RB
with/IN
VHL/NN
,/,
PBRM1/NN
was/VBD
identified/VBN
as/IN
a/DT
major/JJ
gene/NN
,/,
frequently/RB
mutated/VBN
in/IN
renal/JJ
carcinoma/NN
[/(
15/CD
]/)
./.
====================
An/DT
association/NN
with/IN
the/DT
loss/NN
of/IN
its/PRP$
expression/NN
and/CC
renal/JJ
cell/NN
carcinoma/NN
progression/NN
was/VBD
suggested/VBN
in/IN
previous/JJ
studies/NNS
[/(
16/CD
]/)
./.
====================
Mutant/JJ
genes/NNS
dependent/JJ
on/IN
metastasis/NN
====================
We/PRP
found/VBD
that/IN
there/EX
was/VBD
no/DT
difference/NN
in/IN
the/DT
overall/JJ
frequency/NN
of/IN
metastatic/JJ
and/CC
non-metastatic/JJ
samples/NNS
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
The/DT
nine/CD
mutant/JJ
genes/NNS
found/VBN
in/IN
non-metastatic/JJ
samples/NNS
were/VBD
all/DT
included/VBD
in/IN
the/DT
major/JJ
mutant/JJ
genes/NNS
in/IN
the/DT
overall/JJ
samples/NNS
(/(
Fig/NN
./.
====================
3B/NN
)/)
./.
====================
The/DT
lineage-dependent/JJ
frequency/NN
in/IN
non-metastatic/JJ
samples/NNS
was/VBD
also/RB
similar/JJ
with/IN
the/DT
overall/JJ
pattern/NN
in/IN
Fig/NN
./.
====================
3A/NN
./.
====================
However/RB
,/,
half/NN
of/IN
the/DT
15/CD
major/JJ
mutant/JJ
genes/NNS
from/IN
metastatic/JJ
samples/NNS
were/VBD
different/JJ
from/IN
the/DT
mutant/JJ
genes/NNS
in/IN
non-metastatic/JJ
or/CC
overall/JJ
samples/NNS
(/(
Fig/NN
./.
====================
3C/NN
)/)
./.
====================
The/DT
mutations/NNS
of/IN
FAM182B/NN
,/,
LOC653544/NN
,/,
PLEC/NN
,/,
STAG2/NN
,/,
PTPRT/NN
,/,
CSMD3/NN
,/,
and/CC
LRP1B/NN
represented/VBN
unique/JJ
frequencies/NNS
in/IN
metastatic/JJ
samples/NNS
./.
====================
Especially/RB
,/,
PTPRT/NN
is/VBZ
a/DT
member/NN
of/IN
the/DT
protein/NN
tyrosine/NN
phosphatase/NN
(/(
PTP/NN
)/)
family/NN
./.
====================
The/DT
deletion/NN
of/IN
PTPRD/NN
,/,
included/VBD
in/IN
the/DT
same/JJ
PTP/NN
family/NN
,/,
is/VBZ
frequently/RB
seen/VBN
in/IN
metastatic/JJ
cutaneous/JJ
squamous/JJ
cell/NN
carcinoma/NN
[/(
17/CD
]/)
./.
====================
Further/RB
studies/NNS
are/VBP
required/VBN
for/IN
other/JJ
major/JJ
metastasis-associated/JJ
mutant/JJ
genes/NNS
./.
====================
In/IN
conclusion/NN
,/,
the/DT
diversity/NN
of/IN
major/JJ
mutant/JJ
genes/NNS
in/IN
metastatic/JJ
samples/NNS
is/VBZ
quite/RB
different/JJ
from/IN
those/DT
in/IN
non-metastatic/JJ
tumors/NNS
,/,
although/IN
the/DT
overall/JJ
mutation/NN
frequency/NN
is/VBZ
similar/JJ
between/IN
metastatic/JJ
and/CC
non-metastatic/JJ
tumors/NNS
./.
====================
The/DT
present/JJ
study/NN
provides/VBZ
a/DT
useful/JJ
resource/NN
for/IN
understanding/VBG
the/DT
varied/VBN
frequency/NN
of/IN
diverse/JJ
mutations/NNS
in/IN
patients/NNS
'/``
tumor/NN
samples/NNS
./.
====================
Overall/RB
mutation/NN
frequency/NN
in/IN
tissue/NN
samples/NNS
./.
====================
(/(
A/NN
)/)
The/DT
distribution/NN
of/IN
2,938/CD
patient/NN
tissue/NN
samples/NNS
for/IN
the/DT
number/NN
of/IN
mutant/JJ
genes/NNS
per/IN
sample/NN
./.
====================
(/(
B/NN
)/)
The/DT
distribution/NN
of/IN
23,050/CD
mutant/JJ
genes/NNS
for/IN
%/NN
mutation/NN
frequency/NN
./.
====================
(/(
C/NN
)/)
Box/NN
plot/NN
of/IN
the/DT
number/NN
of/IN
mutant/JJ
genes/NNS
per/IN
sample/NN
for/IN
each/DT
caner/NN
subtype/NN
./.
====================
(/(
D/NN
)/)
Box/NN
plot/NN
of/IN
%/NN
sample/NN
frequency/NN
of/IN
individual/JJ
mutation/NN
for/IN
each/DT
caner/NN
subtype/NN
./.
====================
Number/NN
in/IN
the/DT
box/NN
represents/VBZ
median/JJ
value/NN
./.
====================
LUAD/NN
,/,
lung/NN
adenocarcinoma/NN
;/:
LUSC/NN
,/,
lung/NN
squamous/JJ
cell/NN
carcinoma/NN
;/:
OV/NNP
,/,
ovarian/JJ
serous/JJ
cy_stadenocarcinoma/NN
;/:
THCA/NNP
,/,
thyroid/NN
carcinoma/NN
;/:
HNSC/NN
,/,
head/RB
and/CC
neck/NN
squamous/JJ
cell/NN
carcinoma/NN
;/:
GBM/NNP
,/,
glioblastoma/NN
multiforme/JJ
;/:
UCEC/NNP
,/,
uterine/JJ
corpus/FW
endometrioid/JJ
carcinoma/NN
;/:
KIRC/NN
,/,
kidney/NN
renal/JJ
clear/JJ
cell/NN
carcinoma/NN
;/:
COAD/NN
,/,
colon/NN
adenocarcinoma/NN
;/:
BLCA/NNP
,/,
bladder/IN
urothelial/JJ
carcinoma/NN
;/:
READ/NN
,/,
rectum/NN
adenocarcinoma/NN
./.
====================
Comparison/NN
of/IN
mutation/NN
frequency/NN
between/IN
metastatic/JJ
and/CC
non-metastatic/JJ
cancer/NN
samples/NNS
./.
====================
Three/CD
cancer/NN
types-OV/NN
,/,
GBM/NN
,/,
and/CC
UCEC-were/NN
excluded/VBN
,/,
because/IN
the/DT
information/NN
on/IN
metastasis/NN
was/VBD
not/RB
provided/VBN
./.
====================
The/DT
lines/NNS
on/IN
the/DT
bar/JJ
represent/VBP
the/DT
standard/JJ
deviation/NN
for/IN
the/DT
number/NN
of/IN
mutant/JJ
genes/NNS
per/IN
sample/NN
./.
====================
The/DT
numbers/NNS
on/IN
the/DT
dotted/JJ
lines/NNS
represent/VBP
the/DT
value/NN
of/IN
the/DT
standard/JJ
deviation/NN
in/IN
each/DT
sample/NN
./.
====================
The/DT
significant/JJ
difference/NN
between/IN
metastatic/JJ
and/CC
nonmetastatic/JJ
samples/NNS
was/VBD
considered/VBN
based/VBN
on/IN
the/DT
probability/NN
of/IN
t-test/JJS
./.
====================
**p/RB
</JJR
0.01/CD
and/CC
*p/JJ
</JJR
0.1/CD
./.
====================
The/DT
numbers/NNS
under/IN
the/DT
x-axis/NN
show/VBP
the/DT
number/NN
of/IN
metastatic/JJ
and/CC
non-metastatic/JJ
samples/NNS
in/IN
each/DT
cancer/NN
type/NN
./.
====================
LUAD/NN
,/,
lung/NN
adenocarcinoma/NN
;/:
LUSC/NN
,/,
lung/NN
squamous/JJ
cell/NN
carcinoma/NN
;/:
OV/NNP
,/,
ovarian/JJ
serous/JJ
cy_stadenocarcinoma/NN
;/:
THCA/NNP
,/,
thyroid/NN
carcinoma/NN
;/:
HNSC/NN
,/,
head/RB
and/CC
neck/NN
squamous/JJ
cell/NN
carcinoma/NN
;/:
KIRC/NN
,/,
kidney/NN
renal/JJ
clear/JJ
cell/NN
carcinoma/NN
;/:
COAD/NN
,/,
colon/NN
adenocarcinoma/NN
;/:
BLCA/NNP
,/,
bladder/RB
urothelial/JJ
carcinoma/NN
;/:
READ/NN
,/,
rectum/NN
adenocarcinoma/NN
./.
====================
Lineage-dependent/JJ
frequency/NN
of/IN
major/JJ
mutant/NN
genes/NNS
./.
====================
(/(
A/NN
)/)
Heatmap/NN
of/IN
the/DT
12/CD
major/JJ
mutant/JJ
genes/NNS
in/IN
overall/JJ
samples/NNS
./.
====================
Twelve/CD
mutant/JJ
genes/NNS
are/VBP
ranked/VBN
in/IN
the/DT
top/NN
3/CD
in/IN
at/IN
least/JJS
one/CD
cancer/NN
type/NN
based/VBN
on/IN
the/DT
%/NN
frequency/NN
in/IN
the/DT
overall/JJ
samples/NNS
./.
====================
(/(
B/NN
)/)
Heatmap/NN
of/IN
the/DT
17/CD
major/JJ
mutant/JJ
genes/NNS
in/IN
non-metastatic/JJ
samples/NNS
,/,
ranked/VBD
in/IN
the/DT
top/NN
3/CD
in/IN
at/IN
least/JJS
one/CD
cancer/NN
type/NN
based/VBN
on/IN
the/DT
%/NN
frequency/NN
in/IN
metastatic/JJ
and/CC
non-metastatic/JJ
samples/NNS
./.
====================
Two/CD
genes/NNS
colored/VBN
in/IN
blue/JJ
are/VBP
derived/VBN
from/IN
non-metastatic/JJ
samples/NNS
,/,
and/CC
7/CD
genes/NNS
colored/VBN
in/IN
red/JJ
are/VBP
derived/VBN
from/IN
metastatic/JJ
samples/NNS
./.
====================
Others/NNS
colored/JJ
in/IN
black/JJ
are/VBP
commonly/RB
selected/VBN
in/IN
metastatic/JJ
and/CC
non-metastatic/JJ
samples/NNS
./.
====================
(/(
C/NN
)/)
Heatmap/NN
of/IN
the/DT
17/CD
major/JJ
mutant/JJ
genes/NNS
in/IN
metastatic/JJ
samples/NNS
./.
====================
The/DT
list/NN
of/IN
genes/NNS
is/VBZ
the/DT
same/JJ
as/IN
in/IN
Fig/NN
./.
====================
3B/NN
./.
====================
Red/VBN
represents/VBZ
high/JJ
%/NN
frequency/NN
and/CC
yellow/NN
represents/VBZ
low/JJ
%/NN
frequency/NN
./.
====================
In/IN
the/DT
heatmap/NN
for/IN
metastatic/JJ
and/CC
non-metastatic/JJ
samples/NNS
,/,
three/CD
cancer/NN
types-OV/NN
,/,
GBM/NN
,/,
and/CC
UCEC-were/NN
excluded/VBN
,/,
because/IN
the/DT
information/NN
on/IN
metastasis/NN
was/VBD
not/RB
provided/VBN
./.
====================
THCA/DT
,/,
thyroid/NN
carcinoma/NN
;/:
OV/NNP
,/,
ovarian/JJ
serous/JJ
cy_stadenocarcinoma/NN
;/:
LUAD/NNP
,/,
lung/NN
adenocarcinoma/NN
;/:
LUSC/NN
,/,
lung/NN
squamous/JJ
cell/NN
carcinoma/NN
;/:
HNSC/NN
,/,
head/RB
and/CC
neck/NN
squamous/JJ
cell/NN
carcinoma/NN
;/:
BLCA/NNP
,/,
bladder/IN
urothelial/JJ
carcinoma/NN
;/:
COAD/NN
,/,
colon/NN
adenocarcinoma/NN
;/:
READ/NN
,/,
rectum/NN
adenocarcinoma/NN
;/:
GBM/NNP
,/,
glioblastoma/NN
multiforme/JJ
;/:
UCEC/NNP
,/,
uterine/JJ
corpus/FW
endometrioid/JJ
carcinoma/NN
;/:
KIRC/NN
,/,
kidney/NN
renal/JJ
clear/JJ
cell/NN
carcinoma/NN
./.
====================
Survey/NN
of/IN
genome-wide/NN
somatic/JJ
mutations/NNS
in/IN
patient/NN
tumor/NN
samples/NNS
====================
List/NN
of/IN
mutant/JJ
genes/NNS
showing/VBG
high/JJ
mutation/NN
frequency/NN
in/IN
each/DT
cancer/NN
lineage/NN
====================
